<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15154">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00201123</url>
  </required_header>
  <id_info>
    <org_study_id>264</org_study_id>
    <secondary_id>R01HL059832-06</secondary_id>
    <nct_id>NCT00201123</nct_id>
  </id_info>
  <brief_title>Effects of Interferon-Gamma on Cavitary Pulmonary Tuberculosis in the Lungs</brief_title>
  <official_title>Host Response to Tuberculosis and Acquired Immune Deficiency Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York University School of Medicine</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the lung's immune response to mycobacterium tuberculosis (Mtb)
      infection and will modulate that response with interferon-gamma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:

      Mtb infects one-third of the world's population and ranks seventh in terms of global
      morbidity and mortality. Patients with bilateral pulmonary tuberculosis (TB), cavitary
      disease, and persistently positive sputum smears pose a special risk for treatment failure
      and/or relapse.

      DESIGN NARRATIVE:

      Cavitary pulmonary TB will be studied and interferon-gamma will be used as the intervention.
      The outcome of this study will be the changes in mycobacteriology, chest radiography, and
      bronchoalveolar lavage (BAL) cells.

      The primary outcome will be sputum conversion, which will be measured at Weeks 4 and 8.

      The key secondary outcomes of this study will include a chest computerized tomography (CT)
      scan and BAL to measure the flow of cytometry and cytokine levels. Both outcomes will be
      measured at baseline and at Month 4.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Sputum Conversion</measure>
    <time_frame>Measured at Week 4</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Chest CT Scan</measure>
    <time_frame>Measured at Month 4</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bronchoalveolar Lavage (BAL) to Measure Flow of Cytometry and Cytokine Levels</measure>
    <time_frame>Measured at Month 4</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Tuberculosis</condition>
  <condition>AIDS-related Complex</condition>
  <arm_group>
    <arm_group_label>Standard Treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Isoniazid, Rifampin, Pyrazinamide Anti-Tuberculous Therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aerosol Interferon-gamma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aerosol Interferon-Gamma plus Isoniazid, Rifampin, and Pyrazinamide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subcutaneous Interferon-Gamma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous Interferon-Gamma plus Isoniazid, Rifampin, and Pyrazinamide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aerosol Interferon-Gamma</intervention_name>
    <description>Participants will receive aerosol interferon-gamma.</description>
    <arm_group_label>Aerosol Interferon-gamma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Subcutaneous interferon-gamma</intervention_name>
    <description>Patients will receive subcutaneous interferon-gamma</description>
    <arm_group_label>Subcutaneous Interferon-Gamma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Standard Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Positive acid-fast bacillus (AFB) smear within 14 days prior to randomization

          -  Cluster of Differentiation 4 greater than 200 if HIV positive

          -  Ability to sign consent

          -  Bilateral, cavitary pulmonary TB

        Exclusion Criteria:

          -  Multidrug-resistant (MDR) TB

          -  Extrapulmonary TB

          -  HIV positive with opportunistic infection within 30 days of study entry

          -  Cancer

          -  Asthma

          -  Pregnant or lactating women

          -  Chronic heart disease

          -  Chronic liver disease

          -  Chronic renal disease

          -  Seizure disorder

          -  Bleeding or clotting disorder

          -  Diabetes mellitus
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Rom, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NYU School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Lung Institute at University of Cape Town</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Dawson R, Condos R, Tse D, Huie ML, Ress S, Tseng CH, Brauns C, Weiden M, Hoshino Y, Bateman E, Rom WN. Immunomodulation with recombinant interferon-gamma1b in pulmonary tuberculosis. PLoS One. 2009 Sep 15;4(9):e6984. doi: 10.1371/journal.pone.0006984.</citation>
    <PMID>19753300</PMID>
  </results_reference>
  <verification_date>December 2015</verification_date>
  <lastchanged_date>December 2, 2015</lastchanged_date>
  <firstreceived_date>September 16, 2005</firstreceived_date>
  <firstreceived_results_date>January 22, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>AIDS-Related Complex</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferon-gamma</mesh_term>
    <mesh_term>Interferons</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>DOTS Control Group</title>
          <description>DOTS Control Group
IRPE Anti-Tuberculous Therapy: Participants will receive IRPE anti-tuberculous therapy.</description>
        </group>
        <group group_id="P2">
          <title>Aerosol Interferon Gamma for TB</title>
          <description>Aerosol Interferon-Gamma
Aerosol Interferon-Gamma: Participants will receive aerosol interferon-gamma.</description>
        </group>
        <group group_id="P3">
          <title>Subcutaneous Interferon Gamma for TB</title>
          <description>Subcutaneous Interferon-Gamma
Subcutaneous Interferon-Gamma: Partcipants will receive subcutaneous interferon-gamma.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Not Eligible for Clinical Trial</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DOTS Control Group</title>
          <description>IRPE Anti-Tuberculous Therapy
IRPE Anti-Tuberculous Therapy: Participants will receive IRPE anti-tuberculous therapy.</description>
        </group>
        <group group_id="B2">
          <title>Aerosol Interferon Gamma for TB</title>
          <description>Aerosol Interferon-Gamma
Aerosol Interferon-Gamma: Participants will receive aerosol interferon-gamma.</description>
        </group>
        <group group_id="B3">
          <title>Subcutaneous Interferon Gamma for TB</title>
          <description>Subcutaneous Interferon-Gamma
Subcutaneous Interferon-Gamma: Participants will receive subcutaneous interferon-gamma.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="30"/>
                <measurement group_id="B2" value="32"/>
                <measurement group_id="B3" value="27"/>
                <measurement group_id="B4" value="89"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="32" spread="11"/>
                <measurement group_id="B2" value="34" spread="10"/>
                <measurement group_id="B3" value="35" spread="13"/>
                <measurement group_id="B4" value="34" spread="10"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="30"/>
                <measurement group_id="B2" value="32"/>
                <measurement group_id="B3" value="27"/>
                <measurement group_id="B4" value="89"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="8"/>
                <measurement group_id="B3" value="9"/>
                <measurement group_id="B4" value="27"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="24"/>
                <measurement group_id="B3" value="18"/>
                <measurement group_id="B4" value="62"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>South Africa</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="30"/>
                <measurement group_id="B2" value="32"/>
                <measurement group_id="B3" value="27"/>
                <measurement group_id="B4" value="89"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sputum Conversion</title>
        <time_frame>Measured at Week 4</time_frame>
        <safety_issue>No</safety_issue>
        <population>percents</population>
        <group_list>
          <group group_id="O1">
            <title>DOTS Control Group</title>
            <description>IRPE Anti-Tuberculous Therapy
IRPE Anti-Tuberculous Therapy: Participants will receive IRPE anti-tuberculous therapy.</description>
          </group>
          <group group_id="O2">
            <title>Aerosol Interferon Gamma for TB</title>
            <description>Aerosol Interferon-Gamma
Aerosol Interferon-Gamma: Participants will receive aerosol interferon-gamma.</description>
          </group>
          <group group_id="O3">
            <title>Subcutaneous Interferon Gamma for TB</title>
            <description>Subcutaneous Interferon-Gamma
Subcutaneous Interferon-Gamma: Partcipants will receive subcutaneous interferon-gamma.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="32"/>
                  <measurement group_id="O3" value="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Sputum Conversion</title>
            <units>percents</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="36"/>
                  <measurement group_id="O2" value="60"/>
                  <measurement group_id="O3" value="36"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chest CT Scan</title>
        <time_frame>Measured at Month 4</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bronchoalveolar Lavage (BAL) to Measure Flow of Cytometry and Cytokine Levels</title>
        <time_frame>Measured at Month 4</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>DOTS Control Group</title>
          <description>DOTS Control Group
IRPE Anti-Tuberculous Therapy: Participants will receive IRPE anti-tuberculous therapy.</description>
        </group>
        <group group_id="E2">
          <title>Aerosol Interferon Gamma for TB</title>
          <description>Aerosol Interferon-Gamma
Aerosol Interferon-Gamma: Participants will receive aerosol interferon-gamma.</description>
        </group>
        <group group_id="E3">
          <title>Subcutaneous Interferon Gamma for TB</title>
          <description>Subcutaneous Interferon-Gamma
Subcutaneous Interferon-Gamma: Partcipants will receive subcutaneous interferon-gamma.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>hemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Desaturation on BAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>William Rom MD</name_or_title>
      <organization>NYU School of Medicine</organization>
      <phone>212 263-6479</phone>
      <email>William.Rom@nyumc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
